Agendia to Present New FLEX Study Data at ASBrS 2026 Confirming the Consistent Performance of MammaPrint + BluePrint Across Diverse Racial Groups in Genomically Basal-Type Breast Cancer

Multivariate analyses reveal that pathologic complete response is associated Read More

2026-05-01T00:18:06-04:00May 1st, 2026|Press Releases|

Genomic Profiling with MammaPrint ® + BluePrint ® Identifies Aggressive Tumor Subtypes Driving Racial Survival Disparities in HR+/HER2– Early-Stage Breast Cancer

Multicenter study of over 1000 females with breast cancer, Read More

2026-04-06T09:27:36-04:00March 31st, 2026|Press Releases|
Go to Top